BNBurning Rock Biotech Limited BNR · NASDAQ
$12.90 -17.31% (-$2.70)
- Market cap
- ¥110.2M
- Enterprise value
- -¥264.0M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 0.2x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -12.0%
- Gross margin
- 74.6%
- Net margin
- -13.6%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.30
- Free float
- 83.1%
About the company
Burning Rock Biotech Limited (BNR) is a biotechnology company focused on the development and commercialization of diagnostic tests for oncological diseases. Their products include genetic tests and tests for the detection of tumor biomarkers, which help physicians accurately diagnose and treat cancer. Burning Rock Biotech is known for its ability to integrate advanced technologies such as DNA sequencing and artificial intelligence into its diagnostic tests, enabling rapid and precise diagnosis of cancerous diseases. The company also focuses on developing personalized treatment approaches that improve treatment outcomes for cancer patients. Burning Rock Biotech Limited (BNR) shares could be suitable for investors looking for opportunities in the biotechnology sector with an emphasis on cancer diagnosis and treatment.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Yusheng Han
Employees
667
Headquarters
Guangzhou
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number